Dasatinib Drugs Global Market Report 2025

Description

Dasatinib medications are a form of targeted therapy classified as tyrosine kinase inhibitors, mainly utilized in the treatment of blood cancers such as chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). These drugs function by inhibiting proteins that promote cancer cell proliferation, which aids in slowing the progression of the disease. This results in enhanced survival rates and improved disease management.

The primary product types of dasatinib drugs include tablets, oral suspension, and other formulations. Dasatinib is predominantly available in tablet form, providing convenience for patients who need to take it orally. Its various applications encompass chronic myeloid leukemia, acute lymphoblastic leukemia, among others, with several end users such as hospitals, specialty clinics, and home healthcare providers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The dasatinib drugs market research report is one of a series of new reports from The Business Research Company that provides dasatinib drugs market statistics, including dasatinib drugs industry global market size, regional shares, competitors with a dasatinib drugs market share, detailed dasatinib drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the dasatinib drugs industry. This dasatinib drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dasatinib drugs market size has grown strongly in recent years. It will grow from $1.45 billion in 2024 to $1.53 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increase in prevalence of chronic myeloid leukemia (CML), growth in targeted cancer therapies, growth in research on tyrosine kinase inhibitors (TKIS), increase in investment in oncology research, and rise in number of clinical trials.

The dasatinib drugs market size is expected to see strong growth in the next few years. It will grow to $1.95 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing investment in oncology drug pipelines, rising prevalence of drug resistant leukemia cases, growing availability of generic dasatinib drugs, increasing focus on minimizing side effects of chemotherapy, and increasing awareness and early diagnosis of leukemia. Major trends in the forecast period include adoption of personalized medicine, implementation of companion diagnostics, development of new formulations, advancements in combination therapies, and development of biosimilars.

The forecast of 6.3% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. leukemia treatment programs by inflating prices of dasatinib tyrosine kinase inhibitors manufactured in India and Israel, resulting in limited CML therapy options and higher hematologic malignancy costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of chronic myeloid leukemia (CML) is projected to drive growth in the dasatinib drug market in the coming years. CML is a cancer that impacts the bone marrow and blood, characterized by the abnormal proliferation of white blood cells. This increase in prevalence is largely influenced by lifestyle factors, poor dietary habits, and growing environmental risks. Dasatinib is effective in treating CML by inhibiting the BCR-ABL gene fusion, a tyrosine kinase protein resulting from the Philadelphia chromosome mutation that leads to uncontrolled white blood cell growth. For example, in January 2023, the American Cancer Society reported that the number of CML cases in the United States rose to 8,930, up from 8,860 in 2022. Thus, the increasing prevalence of CML is fueling the dasatinib drug market.

Key players in the dasatinib market are concentrating on the development of generic drugs to expand their market presence, provide affordable treatment options, and enhance patient accessibility. Generic versions of dasatinib improve affordability, thus facilitating greater access for patients and fostering competition that can help lower healthcare costs. For instance, in September 2024, Apotex Corp., a Canadian pharmaceutical company, launched the first generic version of Sprycel (dasatinib) in the United States for treating specific types of leukemia in both adults and children. This development significantly enhances access to effective treatments while promoting price competition in the dasatinib market.

In August 2022, Bristol-Myers Squibb, a U.S.-based pharmaceutical company, acquired Turning Point Therapeutics Inc. for $4.1 billion. This acquisition bolsters BMS's cancer treatment portfolio by adding innovative therapies that target genetic mutations, thereby strengthening its position in the competitive lung cancer treatment arena. Turning Point Therapeutics Inc. specializes in developing next-generation tyrosine kinase inhibitors, including dasatinib, aimed at providing targeted therapies for cancer patients.

Major companies operating in the dasatinib drugs market are Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sandoz Group AG, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, MSN Laboratories Pvt. Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Intas Pharmaceuticals Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., Biocon Limited, Alkem Laboratories Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Mylan N.V., Manus Aktteva Biopharma LLP

North America was the largest region in the dasatinib drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dasatinib drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the dasatinib drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dasatinib drugs market consists of sales of sprycel and generic dasatinib. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dasatinib Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dasatinib drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for dasatinib drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The dasatinib drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product Type: Tablets; Oral Suspension; Other Products
2) By Indication: Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia; Other Indications
3) By End User: Hospitals; Specialty Clinics; Home Healthcare
Subsegments:
1) By Tablets: 20 mg Tablets; 50 mg Tablets; 70 mg Tablets; 80 mg Tablets
2) By Oral Suspension: 20 mg Or 5 mL Oral Suspension; 40 mg Or 5 mL Oral Suspension
3) By Other Products: Injectable Formulations; Combination Therapies; Generic Dasatinib Products
Companies Mentioned: Bristol-Myers Squibb Company; AstraZeneca plc; Novartis AG; Gilead Sciences Inc.; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Otsuka Pharmaceutical Co. Ltd.; Sandoz Group AG; Hetero Drugs Limited; Sun Pharmaceutical Industries Limited; MSN Laboratories Pvt. Ltd.; Aurobindo Pharma Limited; Dr. Reddy's Laboratories Limited; Intas Pharmaceuticals Ltd.; Cipla Limited; Hikma Pharmaceuticals plc; Lupin Limited; Zhejiang Hisun Pharmaceutical Co. Ltd.; Biocon Limited; Alkem Laboratories Limited; Glenmark Pharmaceuticals Limited; Torrent Pharmaceuticals Limited; Alembic Pharmaceuticals Limited; Mylan N.V.; Manus Aktteva Biopharma LLP
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r31770u

1. Executive Summary

2. Dasatinib Drugs Market Characteristics

3. Dasatinib Drugs Market Trends And Strategies

4. Dasatinib Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Dasatinib Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Dasatinib Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Dasatinib Drugs Market Growth Rate Analysis
5.4. Global Dasatinib Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Dasatinib Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Dasatinib Drugs Total Addressable Market (TAM)

6. Dasatinib Drugs Market Segmentation

6.1. Global Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tablets
Oral Suspension
Other Products
6.2. Global Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chronic Myeloid Leukemia
Acute Lymphoblastic Leukemia
Other Indications
6.3. Global Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Home Healthcare
6.4. Global Dasatinib Drugs Market, Sub-Segmentation Of Tablets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20 mg Tablets
50 mg Tablets
70 mg Tablets
80 mg Tablets
6.5. Global Dasatinib Drugs Market, Sub-Segmentation Of Oral Suspension, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20 mg Or 5 mL Oral Suspension
40 mg Or 5 mL Oral Suspension
6.6. Global Dasatinib Drugs Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injectable Formulations
Combination Therapies
Generic Dasatinib Products

7. Dasatinib Drugs Market Regional And Country Analysis

7.1. Global Dasatinib Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Dasatinib Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Dasatinib Drugs Market

8.1. Asia-Pacific Dasatinib Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Dasatinib Drugs Market

9.1. China Dasatinib Drugs Market Overview
9.2. China Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Dasatinib Drugs Market

10.1. India Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Dasatinib Drugs Market

11.1. Japan Dasatinib Drugs Market Overview
11.2. Japan Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Dasatinib Drugs Market

12.1. Australia Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Dasatinib Drugs Market

13.1. Indonesia Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Dasatinib Drugs Market

14.1. South Korea Dasatinib Drugs Market Overview
14.2. South Korea Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Dasatinib Drugs Market

15.1. Western Europe Dasatinib Drugs Market Overview
15.2. Western Europe Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Dasatinib Drugs Market

16.1. UK Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Dasatinib Drugs Market

17.1. Germany Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Dasatinib Drugs Market

18.1. France Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Dasatinib Drugs Market

19.1. Italy Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Dasatinib Drugs Market

20.1. Spain Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Dasatinib Drugs Market

21.1. Eastern Europe Dasatinib Drugs Market Overview
21.2. Eastern Europe Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Dasatinib Drugs Market

22.1. Russia Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Dasatinib Drugs Market

23.1. North America Dasatinib Drugs Market Overview
23.2. North America Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Dasatinib Drugs Market

24.1. USA Dasatinib Drugs Market Overview
24.2. USA Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Dasatinib Drugs Market

25.1. Canada Dasatinib Drugs Market Overview
25.2. Canada Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Dasatinib Drugs Market

26.1. South America Dasatinib Drugs Market Overview
26.2. South America Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Dasatinib Drugs Market

27.1. Brazil Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Dasatinib Drugs Market

28.1. Middle East Dasatinib Drugs Market Overview
28.2. Middle East Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Dasatinib Drugs Market

29.1. Africa Dasatinib Drugs Market Overview
29.2. Africa Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Dasatinib Drugs Market Competitive Landscape And Company Profiles

30.1. Dasatinib Drugs Market Competitive Landscape
30.2. Dasatinib Drugs Market Company Profiles
- 30.2.1. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Dasatinib Drugs Market Other Major And Innovative Companies

31.1. Teva Pharmaceutical Industries Ltd.
31.2. Otsuka Pharmaceutical Co. Ltd.
31.3. Sandoz Group AG
31.4. Hetero Drugs Limited
31.5. Sun Pharmaceutical Industries Limited
31.6. MSN Laboratories Pvt. Ltd.
31.7. Aurobindo Pharma Limited
31.8. Dr. Reddy's Laboratories Limited
31.9. Intas Pharmaceuticals Ltd.
31.10. Cipla Limited
31.11. Hikma Pharmaceuticals plc
31.12. Lupin Limited
31.13. Zhejiang Hisun Pharmaceutical Co. Ltd.
31.14. Biocon Limited
31.15. Alkem Laboratories Limited

32. Global Dasatinib Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Dasatinib Drugs Market

34. Recent Developments In The Dasatinib Drugs Market

35. Dasatinib Drugs Market High Potential Countries, Segments and Strategies

35.1 Dasatinib Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Dasatinib Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Dasatinib Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer